{"id":"glatiramer-acetate-copaxone","safety":{"commonSideEffects":[{"rate":"~90%","effect":"Injection site reactions (erythema, induration, pruritus)"},{"rate":"~15-20%","effect":"Immediate post-injection reaction (flushing, chest tightness, dyspnea, palpitations)"},{"rate":"~5-10%","effect":"Lipoatrophy at injection sites"},{"rate":"variable","effect":"Systemic adverse events (headache, nausea, asthenia)"},{"rate":"<1%","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1201507","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glatiramer acetate mimics myelin basic protein and acts as a decoy antigen, shifting the immune response from pro-inflammatory Th1 cells toward anti-inflammatory Th2 and regulatory T cells. This reduces the frequency and severity of relapses in multiple sclerosis by decreasing myelin-reactive immune attacks. The drug also promotes the production of anti-inflammatory cytokines like IL-10 and TGF-β.","oneSentence":"Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell responses, reducing attacks on myelin in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:55.448Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Clinically isolated syndrome (CIS) with MRI features consistent with MS"}]},"trialDetails":[{"nctId":"NCT05344469","phase":"","title":"A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Relapsing Multiple Sclerosis","enrollment":800},{"nctId":"NCT04788615","phase":"PHASE3","title":"Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-23","conditions":"Multiple Sclerosis","enrollment":185},{"nctId":"NCT04821596","phase":"NA","title":"Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2020-07-13","conditions":"Multiple Sclerosis","enrollment":77},{"nctId":"NCT05162638","phase":"NA","title":"Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pennsylvania","startDate":"2022-04-19","conditions":"Multiple Sclerosis, Healthy","enrollment":24},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT05688436","phase":"","title":"A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies","status":"RECRUITING","sponsor":"Biogen","startDate":"2021-09-24","conditions":"Multiple Sclerosis","enrollment":1178},{"nctId":"NCT05767736","phase":"","title":"A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2024-06-08","conditions":"Multiple Sclerosis","enrollment":10500},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT07189325","phase":"PHASE3","title":"A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy","enrollment":250},{"nctId":"NCT05962177","phase":"NA","title":"Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2023-09-11","conditions":"Multiple Sclerosis","enrollment":400},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT04878211","phase":"PHASE4","title":"A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-10","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":24},{"nctId":"NCT03193866","phase":"","title":"COMparison Between All immunoTherapies for Multiple Sclerosis.","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2017-06-02","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":3526},{"nctId":"NCT06663189","phase":"PHASE3","title":"Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-01","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":200},{"nctId":"NCT03362294","phase":"PHASE2","title":"Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mapi Pharma Ltd.","startDate":"2017-12-11","conditions":"Primary Progressive Multiple Sclerosis","enrollment":30},{"nctId":"NCT02212886","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS","status":"COMPLETED","sponsor":"Mapi Pharma Ltd.","startDate":"2014-10","conditions":"Multiple Sclerosis","enrollment":25},{"nctId":"NCT05811949","phase":"","title":"Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.","status":"COMPLETED","sponsor":"IRCCS Centro Neurolesi Bonino Pulejo","startDate":"2021-02-24","conditions":"Multiple Sclerosis","enrollment":52},{"nctId":"NCT05718947","phase":"","title":"Ultra-high-field Brain MRI in Multiple Sclerosis","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2023-09-12","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT03209479","phase":"","title":"Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) \"Prevention of Relapse of Multiple Sclerosis\"","status":"COMPLETED","sponsor":"Teva Takeda Pharma Ltd.","startDate":"2015-11-24","conditions":"Multiple Sclerosis","enrollment":1332},{"nctId":"NCT04472975","phase":"","title":"Prescription Drug Safety and Effectiveness in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"1996-01-01","conditions":"Multiple Sclerosis","enrollment":35000},{"nctId":"NCT03399981","phase":"","title":"Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-06-01","conditions":"Progressive Multifocal Leukoencephalopathy","enrollment":80327},{"nctId":"NCT04448977","phase":"","title":"Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2021-05-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":60},{"nctId":"NCT04121221","phase":"PHASE3","title":"A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS","status":"COMPLETED","sponsor":"Mapi Pharma Ltd.","startDate":"2019-09-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1016},{"nctId":"NCT00988988","phase":"PHASE4","title":"The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2010-02","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT06003972","phase":"PHASE2","title":"Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2021-01-04","conditions":"Acute Decompensated Heart Failure, Cytokine Storm, Inflammatory Response","enrollment":14},{"nctId":"NCT04079088","phase":"PHASE2","title":"Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2021-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT03982212","phase":"PHASE1","title":"A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors","status":"UNKNOWN","sponsor":"University of Kansas Medical Center","startDate":"2019-07-26","conditions":"Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Basal Cell Carcinoma","enrollment":10},{"nctId":"NCT05762003","phase":"","title":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","status":"COMPLETED","sponsor":"IMPULS Endowment Fund","startDate":"2019-01-01","conditions":"Multiple Sclerosis","enrollment":17478},{"nctId":"NCT05528666","phase":"","title":"Risk Perception in Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-09","conditions":"Multiple Sclerosis","enrollment":4361},{"nctId":"NCT05576779","phase":"","title":"Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-03","conditions":"Multiple Sclerosis","enrollment":2101},{"nctId":"NCT01490502","phase":"PHASE3","title":"Vitamin D Supplementation in Multiple Sclerosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":172},{"nctId":"NCT00326625","phase":"PHASE2","title":"Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Teva Pharmaceutical Industries, Ltd.","startDate":"2006-07-27","conditions":"Amyotrophic Lateral Sclerosis","enrollment":366},{"nctId":"NCT01994018","phase":"","title":"Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake","status":"COMPLETED","sponsor":"OSF Healthcare System","startDate":"2011-11","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT02307877","phase":"","title":"Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-09","conditions":"Multiple Sclerosis","enrollment":157},{"nctId":"NCT01067521","phase":"PHASE3","title":"A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-06-22","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":1404},{"nctId":"NCT02499900","phase":"PHASE4","title":"Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-08-10","conditions":"Multiple Sclerosis","enrollment":861},{"nctId":"NCT00176592","phase":"PHASE4","title":"Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2003-01","conditions":"Multiple Sclerosis","enrollment":75},{"nctId":"NCT02753088","phase":"PHASE3","title":"Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":158},{"nctId":"NCT00525668","phase":"PHASE1, PHASE2","title":"Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2007-09","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":120},{"nctId":"NCT04928313","phase":"","title":"Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2015-04-12","conditions":"Relapsing Multiple Sclerosis","enrollment":368},{"nctId":"NCT00937157","phase":"NA","title":"Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2007-09","conditions":"Multiple Sclerosis","enrollment":12},{"nctId":"NCT01623596","phase":"PHASE4","title":"Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06-08","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":881},{"nctId":"NCT03308994","phase":"","title":"Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2017-11-01","conditions":"C10.114.375.500","enrollment":650},{"nctId":"NCT04260711","phase":"NA","title":"Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-07-01","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive","enrollment":130},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT00203021","phase":"PHASE4","title":"Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"1994-03-26","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":208},{"nctId":"NCT02869360","phase":"","title":"Correlation Between PET and Advanced MRI in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2016-10","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT02749396","phase":"","title":"EPID Multiple Sclerosis Pregnancy Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-02","conditions":"Multiple Sclerosis","enrollment":2089},{"nctId":"NCT01633112","phase":"PHASE3","title":"MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08-09","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":1064},{"nctId":"NCT03315923","phase":"PHASE2, PHASE3","title":"Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2017-12-01","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":84},{"nctId":"NCT01498887","phase":"PHASE4","title":"Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-12-24","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":347},{"nctId":"NCT02153723","phase":"PHASE2","title":"Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2013-08","conditions":"Rett Syndrome","enrollment":10},{"nctId":"NCT00939549","phase":"PHASE2","title":"High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2010-11","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT00078338","phase":"PHASE4","title":"Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2004-02-16","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":764},{"nctId":"NCT01569451","phase":"PHASE2","title":"Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-02","conditions":"Multiple Sclerosis","enrollment":53},{"nctId":"NCT01834586","phase":"PHASE4","title":"Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications","status":"COMPLETED","sponsor":"Brown, Theodore R., M.D., MPH","startDate":"2013-03","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT00856635","phase":"PHASE3","title":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-02","conditions":"Optic Neuritis","enrollment":44},{"nctId":"NCT02776072","phase":"","title":"Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-05","conditions":"Multiple Sclerosis","enrollment":2978},{"nctId":"NCT01156311","phase":"PHASE2","title":"BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-06","conditions":"Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis","enrollment":108},{"nctId":"NCT00947752","phase":"PHASE3","title":"Safety of New Formulation of Glatiramer Acetate","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-07","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":147},{"nctId":"NCT00239993","phase":"PHASE4","title":"A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2005-08","conditions":"Multiple Sclerosis","enrollment":50},{"nctId":"NCT01489254","phase":"PHASE3","title":"Efficacy and Safety of GTR in Comparison to Copaxone®","status":"COMPLETED","sponsor":"Synthon BV","startDate":"2011-10","conditions":"Multiple Sclerosis","enrollment":794},{"nctId":"NCT02308670","phase":"","title":"Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2014-07","conditions":"Multiple Sclerosis","enrollment":150},{"nctId":"NCT00039988","phase":"NA","title":"Treatment of Multiple Sclerosis With Copaxone and Albuterol","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-11","conditions":"Autoimmune Diseases, Multiple Sclerosis","enrollment":40},{"nctId":"NCT01903291","phase":"","title":"Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-08","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":333},{"nctId":"NCT00451204","phase":"PHASE2","title":"A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2007-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":158},{"nctId":"NCT01963611","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2013-10","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":255},{"nctId":"NCT01993004","phase":"","title":"Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2013-07","conditions":"Multiple Sclerosis","enrollment":24},{"nctId":"NCT02323269","phase":"","title":"Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)","status":"TERMINATED","sponsor":"Biogen","startDate":"2015-05","conditions":"Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis","enrollment":24},{"nctId":"NCT01874145","phase":"PHASE3","title":"Safety and Tolerability of Glatiramer Acetate","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-06","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":209},{"nctId":"NCT01317004","phase":"PHASE4","title":"Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":61},{"nctId":"NCT01454791","phase":"PHASE4","title":"Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate","status":"COMPLETED","sponsor":"Brown, Theodore R., M.D., MPH","startDate":"2011-01","conditions":"Multiple Sclerosis","enrollment":40},{"nctId":"NCT00451451","phase":"PHASE3","title":"Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-06","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1417},{"nctId":"NCT02017808","phase":"","title":"Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2014-02","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT01419301","phase":"NA","title":"Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2011-05","conditions":"Multiple Sclerosis","enrollment":31},{"nctId":"NCT01058005","phase":"PHASE3","title":"Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis","status":"TERMINATED","sponsor":"Biogen","startDate":"2010-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":84},{"nctId":"NCT01534182","phase":"PHASE4","title":"Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-01","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":298},{"nctId":"NCT00211887","phase":"PHASE3","title":"Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx","status":"COMPLETED","sponsor":"Fred Lublin","startDate":"2005-01","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":1008},{"nctId":"NCT01578785","phase":"PHASE3","title":"An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-03","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":178},{"nctId":"NCT01034579","phase":"PHASE4","title":"The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2010-02","conditions":"Relapsing Multiple Sclerosis","enrollment":324},{"nctId":"NCT01216072","phase":"PHASE4","title":"A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":1053},{"nctId":"NCT02023424","phase":"PHASE1","title":"An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2014-01","conditions":"Rett Syndrome","enrollment":10},{"nctId":"NCT00490906","phase":"","title":"Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis","status":"COMPLETED","sponsor":"Nancy Hammond, MD","startDate":"2007-06","conditions":"Multiple Sclerosis, Low Bone Density","enrollment":60},{"nctId":"NCT00203047","phase":"PHASE4","title":"Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-01","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":414},{"nctId":"NCT01167426","phase":"PHASE3","title":"Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2010-07","conditions":"Multiple Sclerosis","enrollment":148},{"nctId":"NCT00819195","phase":"","title":"Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-12","conditions":"Multiple Sclerosis","enrollment":17},{"nctId":"NCT01071083","phase":"PHASE2","title":"Treatment Interruption of Natalizumab","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-03","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":175},{"nctId":"NCT01936129","phase":"PHASE3","title":"Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2010-09","conditions":"Glaucoma, Angle-closure, Primary, Acute","enrollment":196},{"nctId":"NCT01404117","phase":"PHASE2","title":"A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-03","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT00101959","phase":"PHASE4","title":"Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects","status":"WITHDRAWN","sponsor":"EMD Serono","startDate":"2004-11","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT01626248","phase":"","title":"Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control","status":"COMPLETED","sponsor":"John F. Foley, MD","startDate":"2012-07","conditions":"Multiple Sclerosis","enrollment":164},{"nctId":"NCT00541333","phase":"PHASE1","title":"Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration","status":"SUSPENDED","sponsor":"The New York Eye & Ear Infirmary","startDate":"2007-12","conditions":"Dry Age Related Macular Degeneration","enrollment":15},{"nctId":"NCT01456416","phase":"","title":"Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2011-09","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":10},{"nctId":"NCT01695434","phase":"","title":"A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-06","conditions":"Multiple Sclerosis","enrollment":60},{"nctId":"NCT00819000","phase":"","title":"Therapy Optimization in Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2008-12","conditions":"Multiple Sclerosis","enrollment":2878},{"nctId":"NCT01073813","phase":"PHASE2","title":"Neuroprotection and Repair in Optic Neuritis","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2010-02","conditions":"Multiple Sclerosis, Optic Neuritis","enrollment":6},{"nctId":"NCT00811395","phase":"PHASE2","title":"Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Multiple Sclerosis","enrollment":182},{"nctId":"NCT00475865","phase":"PHASE2","title":"Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-04","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT00666224","phase":"PHASE3","title":"Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-01","conditions":"Multiple Sclerosis","enrollment":481}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":109,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Copaxone (Glatiramer acetate, COP, Copolymer-1)"],"phase":"marketed","status":"active","brandName":"Glatiramer acetate (Copaxone)","genericName":"Glatiramer acetate (Copaxone)","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell responses, reducing attacks on myelin in the central nervous system. Used for Relapsing-remitting multiple sclerosis (RRMS), Clinically isolated syndrome (CIS) with MRI features consistent with MS.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}